ATS

Data from the global RAPID registry provide real-world support for dupilumab efficacy in youths and adults with uncontrolled asthma and with or without CRS and/or nasal polyposis.

Pulmonology experts agreed that adopting race-neutral diagnostic and research practices could help mitigate a range of inequities faced by minority populations.

ATS: The biologic shows promise in a range of people with COPD, particularly those with BEC levels of 150 cells/μL and greater, according to findings released at the 2024 ATS meeting.

The company will present new data on effects of tezepelumab in COPD and of inhaled triple therapy Breztri on cardiopulmonary outcomes in COPD.

In our latest podcast episode, Njira Lugogo, MD, discusses NAVIGATOR data she presented at ATS 2022 that showed clinical responses to treatment with tezepelumab.

ATS 2022: Findings from a literature review provide insight into the mechanisms of airway hyperresponsiveness in asthma.

Njira Lugogo, MD, sat down with Patient Care Online to discuss findings from the prespecified exploratory analysis of the NAVIGATOR study that she presented at ATS 2022.

ATS 2022: Mepolizumab was effective in reducing asthma exacerbations and oral corticosteroid use in real-world clinical practice, according to new research.

ATS 2022: The investigational PDE4B inhibitor slowed pulmonary decline in patients with IPF, both alone and with background use of approved antifibrotics.

ATS 2022. A greater proportion of tezepelumab-treated patients with severe, uncontrolled asthma achieved on-treatment clinical responses than placebo-treated patients.

ATS 2022: A fixed dose SABA/corticosteroid combination reduced risk of exacerbation by 27% vs SABA alone in the MANDALA study.

ATS 2022: Charts from an EHR that included a suspected diagnosis of asthma either had no objective documentation or mentioned a test but included no results.

ATS 2021: In a subgroup of oral corticosteroid-dependent patients with severe asthma from the newly released NAVIGATOR study, tezepelumab reduced exacerbations and improved lung function.

ATS.2021: Odds of uncontrolled asthma in response to pandemic-related stress increased in a significant dose-response manner among adult respondents to a new survey.

ATS.2021. Study authors categorized asthma patients using age at onset, T2 biomarkers, and IL-6 levels, creating 12 phenotypes for additional study.

ATS 2021: The risk of morbidity and death in patients with COPD increases among those with moderate exacerbation, and even more so for severe exacerbation, new research suggests.

In an abstract being presenting at the upcoming ATS 2021 International Conference, researchers estimate that by 2050 the US will lead the Americas in prevalence of COPD.

American Thoracic Society 2021 International Conference: In a subset of patients from the ETHOS study, triple combination therapy was found beneficial for those with moderate COPD.

DALLAS--In a session at the American Thoracic Society meeting this week study authors reported on gaps in post-discharge care for COPD and on tele-rehabilitation as possible bridge. 

DALLAS-Studies on 3 factors that may help guide intervention for patients with ILD were presented: factors during mechanical ventilation, WBC count, and weight loss.

DALLAS--Results of 3 studies presented at the American Thoracic Society meeting this week focus on the predictive role of disease exacerbations, machine learning, and Hgb levels in COPD. 

DALLAS-At the American Thoracic Society meeting thought leaders cited disturbing trends in e-cigarette use by teens and warned of health dangers, known and unknown.

DALLAS--Supplemental oxygen helps patients with lung disease manage better day-to-day, but according to speakers gathered at the ATS meeting in Dallas this week, it can also add to disease burden.

DALLAS--Which patients are candidates for antifibrotic therapy? Is extracorporeal membrane oxygenation appropriate for all ILD patients? The topics were hotly debated on Monday at the American Thoracic Society meeting. 

Dorothy is 55-years-old, has never smoked, and was well until 1 year ago when she first noticed mild dyspnea on exertion; it has gotten progressively worse.

A pulmonologist answers some of the most common questions he hears from colleagues and students about COPD exacerbations and their management.

A pulmonologist describes an approach to guide the primary care clinician faced with a patient in whom interstitial lung disease is suspected.